Improved survival with vemurafenib in melanoma with BRAF V600E mutation - Wikidata - wikimedia - TriplyDB

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

http://www.wikidata.org/entity/Q24631953

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions Evolutionary dynamics of cancer in response to targeted combination therapy TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients Mutational profiling of kinases in glioblastoma.Melanoma: from melanocyte to genetic alterations and clinical options Cancer genome landscapes Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol Educational programmes for primary prevention of skin cancer Interferon alpha for the adjuvant treatment of cutaneous melanoma Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine The Cancer Genome Atlas Pan-Cancer analysis project Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma Melanoma genome sequencing reveals frequent PREX2 mutations Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations Arginine deprivation therapy for malignant melanoma Melanoma immunotherapy dominates the field Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Targeted therapies and immunotherapy in non-small-cell lung cancer FGFR3-TACC3 fusion in solid tumors: mini review Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives From animal models to human disease: a genetic approach for personalized medicine in ALS Targeting MAPK Signaling in Age-Related Macular Degeneration The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers Clinical utility of nivolumab in the treatment of advanced melanoma Cancer immunotherapy: the beginning of the end of cancer?Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network

P2860

75ad27697891b27147082075085c2eeefff99bed

P248

Q21004109-45795E57-BD09-437E-B113-FE4180BD198A Q21128788-CC1D2F98-798C-4851-8021-9AD8BD7C2636 Q21131200-C7FF253B-8DAD-4D8C-9EBF-30D5A2F33E32 Q21131727-32925B18-E307-48E1-B640-1110C798BB83 Q21132689-2965A55E-5854-40A6-950F-F81A045E3731 Q21195817-A52AB294-03CF-418B-9EED-645AD6E6DA46 Q21261249-36C35500-10DA-4ECB-9025-235DAFF0B408 Q21284811-EC30F863-F149-4D68-8ADF-59F59FFEF74E Q22242276-43772C56-4714-47F7-81C6-6CF6C2EECCF0 Q24186719-F517F0E1-F9AA-42AF-8402-5562747FF1AF Q24197687-91D12123-20C8-4F02-B09F-C6FF30688E13 Q24201908-52BA67E1-71AC-48C2-9668-27FC264A3799 Q24294914-73C5620F-1DFE-4E84-A4DE-41A9BB7E1F2C Q24303940-131373F5-673F-428F-B75F-8D93E0EDC9EE Q24304423-87C60127-AA9F-4B85-A463-C47B729D0D15 Q24314807-1E3209D9-051B-44E5-82D5-DF191D6D8961 Q24594790-65308ACE-D1AC-4D50-A008-A21BA887FDA7 Q24604479-13EA3294-8D5F-47D4-AD36-5013461238CF Q24606808-063C8DAC-0326-4327-BD30-E7C5049CCDAC Q24607661-C8226B3B-3A07-427E-AB49-16CD2CA3C0F3 Q24610463-C985BF48-BC90-4AF4-9442-8FDECB672D51 Q24623374-D7D13D82-69EB-410E-BD83-1736ED769737 Q24632064-0B248F80-5AEC-40A7-AE40-032F65CB485F Q24634269-4685D5C3-46A8-4FC0-8A83-A62270FE15C5 Q26738671-E9762FCF-DDB9-4237-8C0E-92C2B3C51A12 Q26738860-6E2A39EA-51B6-417A-89E9-7DA619B23217 Q26738986-39BB214A-1E7F-4419-B2BD-240FFD99DBE2 Q26740578-6DEF2E83-FCF3-44E2-9B0A-FB368D75A907 Q26741009-7ABB7DAD-9974-49C3-87DE-75EEE9C9C403 Q26741250-1D9899B8-DED5-461B-B1D8-A4B6991DAF67 Q26744185-70B6D0D2-AF87-4589-B71B-2C6A3CD83CC2 Q26744335-E3606216-7F95-44E4-B7C6-44758E04B6F6 Q26745767-7FBCC420-C520-4B6C-BF15-89294763C9FE Q26745933-4E0E93FD-D29B-4438-B814-901DBFC757B0 Q26747247-54F1C4DD-4F81-4612-813D-EEA2C0666EE8 Q26747403-8BD9AE26-09C4-4366-A8FD-80679C0CC68A Q26751268-FBEF914E-9EF2-45D7-A597-BF3580D0D22D Q26752277-79B310E6-BD25-49B6-A05E-8FA83D2959C8 Q26752774-BEA699FB-283F-4378-B577-DE391C7D14CC Q26764883-BA59B206-380B-4D56-B343-1FEE9B40C7AA

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

http://www.wikidata.org/entity/Q24631953

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@ast

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@en

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@nl

type

label

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@ast

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@en

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@nl

altLabel

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

@en

prefLabel

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@ast

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@en

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

@nl

P1433

Q24631953-331211F2-04F1-4A46-B199-1D9E8FBD9AA1

P1476

Q24631953-3CEEE761-8669-4097-9CD9-C1E58961A96B

P2093

Q24631953-0761F2B7-8377-4633-A8F9-172839816E6C

Q24631953-0F1453C4-CEB6-46BB-9809-B7807B1E025F

Q24631953-14C59A78-03E9-4606-8D0D-D36EDE06EC96

Q24631953-207C43D6-2C44-4EC8-AAFE-E2D81556A123

Q24631953-29EED3E5-3A80-4C16-8214-E02D8312D3AB

Q24631953-5AFFF164-67F1-430D-B21B-E18831A336CE

Q24631953-6B4EF1D2-15D7-4F4B-958E-8EB81C16304B

Q24631953-76F88180-7C59-4AC5-9080-E505CD1B4185

Q24631953-813D83B8-CAB1-4731-A77D-3E297C31B842

Q24631953-8960B8CA-313E-463C-BD74-299DAC3A8013

P2860

Q24631953-057106F1-6EDA-4203-A15F-31490CB84991

Q24631953-0F83A01B-57E5-4243-9823-DC51DB3BC739

Q24631953-2217F4DB-A1B9-4EA8-903F-6B805DE935CD

Q24631953-2EBB3605-882B-470B-A79C-8FEC8ABFE379

Q24631953-38E1FDA5-4BCE-493D-80F4-9F272E1558F0

Q24631953-59599A5E-0425-43BB-95A5-0C91CDFB3C0B

Q24631953-5AB0CCF0-9733-4080-8293-492F285ADB5F

Q24631953-614491D3-79F2-4F24-8359-EB070FE582C8

Q24631953-64E153F5-9BD6-404F-8D64-82ED9D565A42

Q24631953-6E82AB8A-F950-4004-BDA4-156ECD76DF77

P304

Q24631953-26E1D802-2FAB-4C03-B85F-FD1C35086104

P31

Q24631953-AF1A97A6-D268-4F2A-BFE5-19038BCB1300

P3181

Q24631953-C42862C9-BE08-4586-A8CC-D123F1E798EF

P356

Q24631953-344E232D-CB8A-4EC0-B2C6-45E8F947954F

P407

Q24631953-0EDCC94C-D60A-494B-80EF-A472CE8CC692

P433

Q24631953-B80C8CE6-1B66-42B7-8922-531096E9C03D

P478

Q24631953-219C3F03-A886-4A2F-9EC3-F56BBEFD599D

P50

Q24631953-12BA2336-01E7-4688-99C8-FE4BB0DB1160

Q24631953-2D1CE939-9660-4BBB-B5BA-AA9AC60AB12A

Q24631953-3042E24C-B850-405C-8C79-4EDA2C8ED06D

Q24631953-327AB991-1FCE-46D5-A9F1-4251F9A127DD

Q24631953-4EB8A682-1F81-4E57-985D-BA1EFCEE42DD

Q24631953-5A3C1E30-8A43-4A86-BB80-81FCF8FB6380

Q24631953-6BD79A92-029E-49E2-A72C-C650F78AD5C8

Q24631953-912A37CE-FFCD-47FD-BF90-99A2B0BA4F91

Q24631953-D8E94011-3B9A-4F34-80A2-7E249EFD9DD1

Q24631953-E3797422-A31F-4BDF-9E65-BEA5FE175265

P5008

Q24631953-26B8BFD9-1931-47FB-8403-5B30D740B421

P577

Q24631953-DB85CCD8-02E7-4FE5-991B-C42193D9B467

P698

Q24631953-6FF4A18A-824F-4CDD-967F-C979E9CF69AF

P921

Q24631953-3966600d-45cb-02f4-b50b-da881d0ca547

Q24631953-7396ae47-461a-92a5-683d-5458bd14de17

P932

Q24631953-FC88DE71-AEA3-441F-91C0-CF8CA17349D6

P3181

P356

P1433

The New England Journal of Medicine

P1476

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

@en

P2093

Alessandro Testori

http://www.w3.org/2001/XMLSchema#string

Alexander M M Eggermont

http://www.w3.org/2001/XMLSchema#string

Betty Nelson

http://www.w3.org/2001/XMLSchema#string

Brigitte Dreno

http://www.w3.org/2001/XMLSchema#string

Celeste Lebbe

http://www.w3.org/2001/XMLSchema#string

David Hogg

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

Jeannie Hou

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Jiang Li

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Cancer statistics, 2010

Mutations of the BRAF gene in human cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

2507-16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

144205

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1103782

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Eggermont

Dirk Schadendorf

Reinhard Dummer

Paolo Antonio Ascierto

Caroline Robert

P5008

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21639808

http://www.w3.org/2001/XMLSchema#string

P921

P932

3549296

http://www.w3.org/2001/XMLSchema#string